Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Phase 3 registrational trial ALLOHA-2 in AML/MDS undergoing allogeneic HCT; first patient dosed Jul 2026. Phase 1 ALLOHA trial ongoing.
TSC-102-A01
Stage not disclosed · ActiveModality: TCR-engineered T cell (TCR-T) therapy (allogeneic, donor-derived)
Target CD45 (HLA-A*01:01)
Indications
Hematologic malignancies undergoing HCT(Stage not disclosed)
Status note Donor-derived TCR-T candidate targeting CD45 in patients with HLA type A*01:01 undergoing HCT.
TSC-102-A03
Stage not disclosed · ActiveModality: TCR-engineered T cell (TCR-T) therapy (allogeneic, donor-derived)
Target CD45 (HLA-A*03:01)
Indications
Hematologic malignancies undergoing HCT(Stage not disclosed)
Status note Donor-derived TCR-T candidate targeting CD45 in patients with HLA type A*03:01 undergoing HCT.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Head and Neck Cancer; Cervical Cancer; Non Small Cell Lung Cancer
—
Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.